Track record · closed signal

Sarepta Therapeutics Inc (SRPT) — closed signal from June 17, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on September 15, 2026 — +21.4% at the close.

Predicted vs. what happened

SRPT price · publication thesis → realized outcomesplit-adjusted

$16.20 – $17.30Entry zone — fair-value band

$17.07Published — price the day we called it

$19.45Target — the price the thesis aimed for

$23.62Peak — highest point inside the window, not a realized return

$20.72Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 15 days.

At window close

+21.4%

realized, from the publication price to the last close inside the window

Peak gain

+38.4%

peak, from the publication price — not a realized return

S&P 500, same window

+2.5%

SPY over the identical days, dividend-adjusted

Window close

$20.72

last close inside the window, ended September 15, 2026

Peak price

$23.62

peak on September 2, 2026 — not a realized return

Days to target

The thesis — published June 17, 2026

Predicted growth

+14%

over the measurement window

Target price

$19.45

the price the thesis aimed for

Entry zone

$16.20 – $17.30

the fair-value band we waited for

Price at publication

$17.07

published June 17, 2026

Confidence

65%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Sarepta looks like a risky rebound trade, not a main holding. An upgrade tied to higher earnings estimates helped the story that the company can be profitable, but a big planned share sale threatens dilution. Weak sales, unpredictable results, and biotech headline risk mean the near-term case relies on improving investor sentiment before broader support appears.

Primary drivers

Improved short-term story from a profitability update
Upgrade lifted expectations and helped market sentiment
Planned equity sale raises dilution concerns
Biotech headlines and uneven results make it speculative

How it played out

SRPT: target reached in 15 days

Lyra published SRPT at $17.07 as a risky short-term rebound trade rather than a core holding. It expected 14% growth toward $19.45. The thesis pointed to a profitability update and an upgrade that had lifted expectations, while flagging a planned share sale, dilution risk, weak sales, uneven results, and biotech headlines.

The price reached the target in 15 days. It later peaked at $23.62 on September 2, a gain of 38.4%. By September 15, it ended at $20.72, still above the target. The thesis played out.

What happened during the window

On June 30, Sarepta said the FDA had accepted supplemental applications for AMONDYS 45 and VYONDYS 53. On August 5, the company reported second-quarter net product revenue of $328.7 million and GAAP operating income of $13.3 million.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All SRPT signals